PDF(Pubmed)
Abstract：
OBJECTIVE: Relapsed/refractory extramedullary myeloma (RREMM) is an uncommon and aggressive subtype of multiple myeloma defined by plasma cell proliferation outside the bone marrow. Therapeutic options for RREMM are limited, and the prognosis is generally unfavorable. This research aimed to assess the effectiveness of the bendamustine, pomalidomide, and dexamethasone (BPD) regimen in patients with RREMM.
METHODS: We carried out a retrospective investigation of 11 RREMM patients who underwent BPD treatment. The primary endpoint was progression-free survival. The secondary endpoints of the study were two-year survival and overall response rate (ORR). We analyzed the sociodemographic and clinical features of the patients.
RESULTS: The average age of the patients was 62 years. They had a median of four prior treatment lines, and eight patients had previously received autologous stem-cell transplantation. After eight BPD treatment cycles, the ORR stood at 54%, with one very good partial response (VGPR), five partial responses (PR), three progressive diseases (PD), and two stable diseases (SD). The median follow-up was 15 months, with a two-year PFS rate of 71.3% and a two-year survival rate of 81.8%.
CONCLUSIONS: The BPD regimen demonstrated promising effectiveness in RREMM patients, yielding favorable ORR and survival rates. To corroborate these findings and explore additional treatment alternatives for this patient group, larger prospective studies are required.
METHODS: We carried out a retrospective investigation of 11 RREMM patients who underwent BPD treatment. The primary endpoint was progression-free survival. The secondary endpoints of the study were two-year survival and overall response rate (ORR). We analyzed the sociodemographic and clinical features of the patients.
RESULTS: The average age of the patients was 62 years. They had a median of four prior treatment lines, and eight patients had previously received autologous stem-cell transplantation. After eight BPD treatment cycles, the ORR stood at 54%, with one very good partial response (VGPR), five partial responses (PR), three progressive diseases (PD), and two stable diseases (SD). The median follow-up was 15 months, with a two-year PFS rate of 71.3% and a two-year survival rate of 81.8%.
CONCLUSIONS: The BPD regimen demonstrated promising effectiveness in RREMM patients, yielding favorable ORR and survival rates. To corroborate these findings and explore additional treatment alternatives for this patient group, larger prospective studies are required.
摘要：
目的：复发/难治性髓外骨髓瘤（RREMM）是一种罕见且侵袭性的多发性骨髓瘤亚型，其定义为骨髓外的浆细胞增殖。RREMM的治疗选择有限，预后普遍不利。这项研究旨在评估苯达莫司汀的有效性，泊马度胺,和地塞米松（BPD）方案在RREMM患者中的应用。
方法：我们对11例接受BPD治疗的RREMM患者进行了回顾性调查。主要终点是无进展生存期。研究的次要终点是2年生存率和总有效率（ORR）。我们分析了患者的社会人口统计学和临床特征。
结果：患者的平均年龄为62岁。他们有四个先前治疗线的中位数，8例患者之前接受过自体干细胞移植.八个BPD治疗周期后，ORR为54%，有一个非常好的部分反应(VGPR)，五个部分响应(PR)，三种进行性疾病（PD），和两种稳定的疾病（SD）。中位随访时间为15个月,两年PFS率为71.3%，两年生存率为81.8%。
结论：BPD方案在RREMM患者中具有良好的疗效，产生良好的ORR和存活率。为了证实这些发现，并为该患者组探索其他治疗方案，需要更大的前瞻性研究。
方法：我们对11例接受BPD治疗的RREMM患者进行了回顾性调查。主要终点是无进展生存期。研究的次要终点是2年生存率和总有效率（ORR）。我们分析了患者的社会人口统计学和临床特征。
结果：患者的平均年龄为62岁。他们有四个先前治疗线的中位数，8例患者之前接受过自体干细胞移植.八个BPD治疗周期后，ORR为54%，有一个非常好的部分反应(VGPR)，五个部分响应(PR)，三种进行性疾病（PD），和两种稳定的疾病（SD）。中位随访时间为15个月,两年PFS率为71.3%，两年生存率为81.8%。
结论：BPD方案在RREMM患者中具有良好的疗效，产生良好的ORR和存活率。为了证实这些发现，并为该患者组探索其他治疗方案，需要更大的前瞻性研究。
